##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 9 (2025)

Video-Observed Therapy as an alternative to Directly-Observed Therapy for active tuberculosis: a prospective study of feasibility and acceptability by patients and nurses in a low-incidence high-income area

Cite this as:
Swiss Med Wkly. 2025;155:4238
Published
01.09.2025

Summary

STUDY AIM: Tuberculosis remains a public health issue in Switzerland. Adherence to treatment is a challenge. To promote adherence, Video-Observed Therapy (VOT) has been proposed as an alternative to Directly Observed Therapy (DOT) that is less stigmatising, respects patients’ privacy and uses less resources. This study aimed to assess (1) the feasibility and (2) the acceptability of VOT for tuberculosis by patients and specialised nurses in our area.

METHODS: All subjects aged above 16 years with a newly diagnosed active tuberculosis, irrespective of site of infection, and followed by our centre could be included. Patients were provided with a pictogram-based smartphone app and trained by specialised nurses to send daily videos of their treatment to a secure platform. Acceptability by patients and by specialised nurses, ratio of number of videos sent to those expected and technical issues were prospectively recorded.

RESULTS: Over 18 months, 55 patients were invited to participate. Four (7.2%) declined (92.7% acceptance rate). Of the remaining 51, 5 (9.8%) failed to start VOT, thus leaving 46 patients followed by VOT (their median age was 40.3 years with interquartile range [IQR] 33–45; 27 [53%] were female). Three cases (6.5%) dropped out. No cases of multidrug-resistant tuberculosis were documented. The ratio of total number of videos received/ expected (5744/6392) was 89.9%; the median individual ratio of videos sent/received was 96% (IQR: 73–100); the number of videos sent remained stable over 6 months. Of the 5744 videos sent, 312 (5.4%) showed minor technical problems. Results of an 18-item questionnaire showed that VOT was well accepted by our specialised nurses.

CONCLUSIONS: VOT showed a high rate of acceptance by patients and specialised nurses in our area and appears to be a feasible alternative to DOT.

References

  1. 1. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994 Apr;330(17):1179–84. doi: https://doi.org/10.1056/NEJM199404283301702
  2. 2. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018 Jul;15(7):e1002595. doi: https://doi.org/10.1371/journal.pmed.1002595
  3. 3. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015 May;2015(5):CD003343. doi: https://doi.org/10.1002/14651858.CD003343.pub4
  4. 4. Holzschuh EL, Province S, Johnson K, Walls C, Shemwell C, Martin G, et al. Use of Video Directly Observed Therapy for Treatment of Latent Tuberculosis Infection - Johnson County, Kansas, 2015. MMWR Morb Mortal Wkly Rep. 2017 Apr;66(14):387–9. doi: https://doi.org/10.15585/mmwr.mm6614a3
  5. 5. Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation of video-observed therapy in an urban TB program in the United States. Int J Tuberc Lung Dis. 2021 Aug;25(8):655–61. doi: https://doi.org/10.5588/ijtld.21.0170
  6. 6. Bendiksen R, Ovesen T, Asfeldt AM, Halvorsen DS, Gravningen K. Use of video directly observed treatment for tuberculosis in Northern Norway [Bruk av videosamtale i behandling av tuberkulose-sykdom i Nord-Norge]. Tidsskr Nor Laegeforen. 2020 Jan;140(1).
  7. 7. Beeler Asay GR, Lam CK, Stewart B, Mangan JM, Romo L, Marks SM, et al. Cost of Tuberculosis Therapy Directly Observed on Video for Health Departments and Patients in New York City; San Francisco, California; and Rhode Island (2017-2018). Am J Public Health. 2020 Nov;110(11):1696–703. doi: https://doi.org/10.2105/AJPH.2020.305877
  8. 8. Garfein RS, Doshi RP. Synchronous and asynchronous video observed therapy (VOT) for tuberculosis treatment adherence monitoring and support. J Clin Tuberc Other Mycobact Dis. 2019 Apr;17:100098. doi: https://doi.org/10.1016/j.jctube.2019.100098
  9. 9. Guo X, Yang Y, Takiff HE, Zhu M, Ma J, Zhong T, et al. A Comprehensive App That Improves Tuberculosis Treatment Management Through Video-Observed Therapy: usability Study. JMIR Mhealth Uhealth. 2020 Jul;8(7):e17658. doi: https://doi.org/10.2196/17658
  10. 10. Lam CK, Fluegge K, Macaraig M, Burzynski J. Cost savings associated with video directly observed therapy for treatment of tuberculosis. Int J Tuberc Lung Dis. 2019 Nov;23(11):1149–54. doi: https://doi.org/10.5588/ijtld.18.0625
  11. 11. Nguyen TA, Pham MT, Nguyen TL, Nguyen VN, Pham DC, Nguyen BH, et al. Video Directly Observed Therapy to support adherence with treatment for tuberculosis in Vietnam: A prospective cohort study. Int J Infect Dis. 2017 Dec;65:85–9. doi: https://doi.org/10.1016/j.ijid.2017.09.029
  12. 12. Olano-Soler H, Thomas D, Joglar O, Rios K, Torres-Rodríguez M, Duran-Guzman G, et al. Notes from the Field: Use of Asynchronous Video Directly Observed Therapy for Treatment of Tuberculosis and Latent Tuberculosis Infection in a Long-Term-Care Facility - Puerto Rico, 2016-2017. MMWR Morb Mortal Wkly Rep. 2017 Dec;66(50):1386–7. doi: https://doi.org/10.15585/mmwr.mm6650a5
  13. 13. Ravenscroft L, Kettle S, Persian R, Ruda S, Severin L, Doltu S, et al. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J. 2020 Aug;56(2):2000493. doi: https://doi.org/10.1183/13993003.00493-2020
  14. 14. Rodrigues R, Varghese SS, Mahrous M, Ananthaneni Kumar A, Ahmed MN, D’Souza G. Feasibility and acceptability pilot of video-based direct observed treatment (vDOT) for supporting antitubercular treatment in South India: a cohort study. BMJ Open. 2023 May;13(5):e065878. doi: https://doi.org/10.1136/bmjopen-2022-065878
  15. 15. Sinkou H, Hurevich H, Rusovich V, Zhylevich L, Falzon D, de Colombani P, et al. Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience. Eur Respir J. 2017 Mar;49(3):1602049. doi: https://doi.org/10.1183/13993003.02049-2016
  16. 16. Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis. 2016 May;20(5):588–93. doi: https://doi.org/10.5588/ijtld.15.0738
  17. 17. Lippincott CK, Perry A, Munk E, Maltas G, Shah M. Tuberculosis treatment adherence in the era of COVID-19. BMC Infect Dis. 2022 Oct;22(1):800. doi: https://doi.org/10.1186/s12879-022-07787-4
  18. 18. Story A, Aldridge RW, Smith CM, Garber E, Hall J, Ferenando G, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019 Mar;393(10177):1216–24. doi: https://doi.org/10.1016/S0140-6736(18)32993-3
  19. 19. Areas Lisboa Netto T, Diniz BD, Odutola P, Dantas CR, de Freitas MC, Hefford PM, et al. Video-observed therapy (VOT) vs directly observed therapy (DOT) for tuberculosis treatment: A systematic review on adherence, cost of treatment observation, time spent observing treatment and patient satisfaction. PLoS Negl Trop Dis. 2024 Oct;18(10):e0012565. doi: https://doi.org/10.1371/journal.pntd.0012565
  20. 20. Burzynski J, Mangan JM, Lam CK, Macaraig M, Salerno MM, deCastro BR, et al.; eDOT Study Team. In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial. JAMA Netw Open. 2022 Jan;5(1):e2144210. doi: https://doi.org/10.1001/jamanetworkopen.2021.44210
  21. 21. Schoch OD, Barben J, Berger C, Böttger EC, Egger JM, Fenner L, et al. Tuberculosis in Switzerland. Guidance for healthcare professionals Bern, Switzerland; 2021. Available from: https://www.liguepulmonaire.ch/centre-de-competence-tuberculose/directives
  22. 22. Kherad O, Herrmann FR, Zellweger JP, Rochat T, Janssens JP. Clinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland. BMC Infect Dis. 2009 Dec;9(1):217. doi: https://doi.org/10.1186/1471-2334-9-217
  23. 23. Bachina P, Lippincott CK, Perry A, Munk E, Maltas G, Bohr R, et al. Programmatic Adoption and Implementation of Video-Observed Therapy in Minnesota: Prospective Observational Cohort Study. JMIR Form Res. 2022 Aug;6(8):e38247. doi: https://doi.org/10.2196/38247
  24. 24. Holzman SB, Atre S, Sahasrabudhe T, Ambike S, Jagtap D, Sayyad Y, et al. Use of Smartphone-Based Video Directly Observed Therapy (vDOT) in Tuberculosis Care: Single-Arm, Prospective Feasibility Study. JMIR Form Res. 2019 Aug;3(3):e13411. doi: https://doi.org/10.2196/13411
  25. 25. Holzman SB, Zenilman A, Shah M. Advancing Patient-Centered Care in Tuberculosis Management: A Mixed-Methods Appraisal of Video Directly Observed Therapy. Open Forum Infect Dis. 2018 Apr;5(4):ofy046. doi: https://doi.org/10.1093/ofid/ofy046
  26. 26. Sekandi JN, Buregyeya E, Zalwango S, Dobbin KK, Atuyambe L, Nakkonde D, et al. Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. ERJ Open Res. 2020 Apr;6(1):00175–02019. doi: https://doi.org/10.1183/23120541.00175-2019
  27. 27. Nsengiyumva NP, Khan A, Gler MM, Tonquin ML, Marcelo D, Andrews MC, et al. Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021. Emerg Infect Dis. 2024 Jan;30(1):79–88. doi: https://doi.org/10.3201/eid3001.230427
  28. 28. Garfein RS, Liu L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, et al. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis. 2018 Oct;24(10):1806–15. doi: https://doi.org/10.3201/eid2410.180459
  29. 29. Ting NC, El-Turk N, Chou MS, Dobler CC. Patient-perceived treatment burden of tuberculosis treatment. PLoS One. 2020 Oct;15(10):e0241124. doi: https://doi.org/10.1371/journal.pone.0241124
  30. 30. Chen EC, Owaisi R, Goldschmidt L, Maimets IK, Daftary A. Patient perceptions of video directly observed therapy for tuberculosis: a systematic review. J Clin Tuberc Other Mycobact Dis. 2023 Nov;35:100406. doi: https://doi.org/10.1016/j.jctube.2023.100406
  31. 31. Sekandi JN, McDonald A, Nakkonde D, Zalwango S, Kasiita V, Kaggwa P, et al. Acceptability, Usefulness, and Ease of Use of an Enhanced Video Directly Observed Treatment System for Supporting Patients With Tuberculosis in Kampala, Uganda: Explanatory Qualitative Study. JMIR Form Res. 2023 Nov;7:e46203. doi: https://doi.org/10.2196/46203
  32. 32. Sekandi JN, Kasiita V, Onuoha NA, Zalwango S, Nakkonde D, Kaawa-Mafigiri D, et al. Stakeholders’ Perceptions of Benefits of and Barriers to Using Video-Observed Treatment for Monitoring Patients With Tuberculosis in Uganda: Exploratory Qualitative Study. JMIR Mhealth Uhealth. 2021 Oct;9(10):e27131. doi: https://doi.org/10.2196/27131
  33. 33. Rabinovich L, Molton JS, Ooi WT, Paton NI, Batra S, Yoong J. Perceptions and Acceptability of Digital Interventions Among Tuberculosis Patients in Cambodia: Qualitative Study of Video-Based Directly Observed Therapy. J Med Internet Res. 2020 Jul;22(7):e16856. doi: https://doi.org/10.2196/16856